Discovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms

Neha Bhagwat1, Duanya Liu2, Xiaowei Wu1, Alexander Grego1, Amy Crossan1, Andrew Moore1, Arpita Mondal1, Carly Bachner1, Dani Roth1, Diego Elrio, John Rose1, Joseph Rager1, Joy Cote1, Kirsten Gallagher1, Klare Bersch1, Miles Cowart1, Min Wang1, Natalie Kurtz1, Norman Fultang1, SharayuChandratre1, Song Mei1, Srijita Dhar1, Sushanta Ratna1, Stephanie Rodgers1, Yann Loret1, Yue Zou1, Sandy Geeganage1, Andrew Combs1, Jean-Jacques Kiladjian2, Stephane Giraudier2, Peggy Scherle1